The estimated Net Worth of Brian Mueller is at least 13.8 百万$ dollars as of 30 May 2024. Mr Mueller owns over 5,000 units of Biomarin Pharmaceutical stock worth over 6,541,540$ and over the last 14 years he sold BMRN stock worth over 6,255,292$. In addition, he makes 985,513$ as Exec. VP of Fin. & CFO at Biomarin Pharmaceutical.
Mr has made over 33 trades of the Biomarin Pharmaceutical stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of BMRN stock worth 315,500$ on 30 May 2024.
The largest trade he's ever made was selling 16,831 units of Biomarin Pharmaceutical stock on 30 April 2013 worth over 1,113,707$. On average, Mr trades about 2,231 units every 57 days since 2011. As of 30 May 2024 he still owns at least 77,159 units of Biomarin Pharmaceutical stock.
You can see the complete history of Mr Mueller stock trades at the bottom of the page.
Brian R. Mueller is the Exec. VP of Fin. & CFO at Biomarin Pharmaceutical.
As the Exec. VP of Fin. & CFO of Biomarin Pharmaceutical, the total compensation of Mr Mueller at Biomarin Pharmaceutical is 985,513$. There are 8 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of 18,405,900$.
Mr Mueller is 47, he's been the Exec. VP of Fin. & CFO of Biomarin Pharmaceutical since . There are 19 older and 3 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over 153,109,113$ worth of Biomarin Pharmaceutical stock and bought 151,118 units worth 2,557,509$ . The most active insiders traders include Jean Jacques Bienaime、Mark J Enyedy、Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of 912,996$. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth 64,260$.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: